Company Registration No. 10657848 (England and Wales)
TRAD-AC THERAPIES LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2026
PAGES FOR FILING WITH REGISTRAR
Celixir House
Stratford Business & Technology Park
Innovation Way, Banbury Road
Stratford-upon-Avon
Warwickshire
United Kingdom
CV37 7GZ
TRAD-AC THERAPIES LIMITED
CONTENTS
Page
Company information
1
Balance sheet
2 - 3
Notes to the financial statements
4 - 7
TRAD-AC THERAPIES LIMITED
COMPANY INFORMATION
- 1 -
Directors
Mrs S E Duncan
Mr R S Duncan
Company number
10657848
Registered office
Celixir House
Stratford Business & Technology Park
Innovation Way, Banbury Road
Stratford-upon-Avon
Warwickshire
United Kingdom
CV37 7GZ
Accountants
TC Group
Celixir House
Stratford Business & Technology Park
Innovation Way, Banbury Road
Stratford-upon-Avon
Warwickshire
United Kingdom
CV37 7GZ
TRAD-AC THERAPIES LIMITED
BALANCE SHEET
AS AT
31 MARCH 2026
31 March 2026
- 2 -
2026
2025
Notes
£
£
£
£
Fixed assets
Tangible assets
3
315,123
315,123
Current assets
Debtors
4
6,626
1,081
Cash at bank and in hand
4,364
3,377
10,990
4,458
Creditors: amounts falling due within one year
5
(32,174)
(27,456)
Net current liabilities
(21,184)
(22,998)
Total assets less current liabilities
293,939
292,125
Creditors: amounts falling due after more than one year
6
(230,264)
(262,354)
Net assets
63,675
29,771
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
63,575
29,671
Total equity
63,675
29,771

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

TRAD-AC THERAPIES LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2026
31 March 2026
- 3 -
The financial statements were approved by the board of directors and authorised for issue on 26 May 2026 and are signed on its behalf by:
Mr R S Duncan
Director
Company registration number 10657848 (England and Wales)
TRAD-AC THERAPIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
- 4 -
1
Accounting policies
Company information

Trad-AC Therapies Limited is a private company limited by shares incorporated in England and Wales. The registered office is Celixir House, Stratford Business & Technology Park, Innovation Way, Banbury Road, Stratford-upon-Avon, Warwickshire, United Kingdom, CV37 7GZ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recover ed.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold land and buildings
Not provided
Computers
33% straight line basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

TRAD-AC THERAPIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 5 -
1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

TRAD-AC THERAPIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 6 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
-
0
1
3
Tangible fixed assets
Freehold land and buildings
Computers
Total
£
£
£
Cost
At 1 April 2025 and 31 March 2026
315,123
1,001
316,124
Depreciation and impairment
At 1 April 2025 and 31 March 2026
-
0
1,001
1,001
Carrying amount
At 31 March 2026
315,123
-
0
315,123
At 31 March 2025
315,123
-
0
315,123
TRAD-AC THERAPIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 7 -
4
Debtors
2026
2025
Amounts falling due within one year:
£
£
Trade debtors
6,626
-
0
Other debtors
-
0
1,081
6,626
1,081
5
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
515
434
Taxation and social security
8,259
4,137
Other creditors
23,400
22,885
32,174
27,456
6
Creditors: amounts falling due after more than one year
2026
2025
£
£
Other creditors
230,264
262,354
2026-03-31 2025-04-01 false false false 26 May 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mrs S E Duncan Mr R S Duncan 10657848 2025-04-01 2026-03-31 10657848 bus:Director1 2025-04-01 2026-03-31 10657848 bus:Director2 2025-04-01 2026-03-31 10657848 bus:RegisteredOffice 2025-04-01 2026-03-31 10657848 2026-03-31 10657848 2025-03-31 10657848 core:LandBuildings core:OwnedOrFreeholdAssets 2026-03-31 10657848 core:ComputerEquipment 2026-03-31 10657848 core:LandBuildings core:OwnedOrFreeholdAssets 2025-03-31 10657848 core:ComputerEquipment 2025-03-31 10657848 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 10657848 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 10657848 core:Non-currentFinancialInstruments core:AfterOneYear 2026-03-31 10657848 core:Non-currentFinancialInstruments core:AfterOneYear 2025-03-31 10657848 core:CurrentFinancialInstruments 2026-03-31 10657848 core:CurrentFinancialInstruments 2025-03-31 10657848 core:ShareCapital 2026-03-31 10657848 core:ShareCapital 2025-03-31 10657848 core:RetainedEarningsAccumulatedLosses 2026-03-31 10657848 core:RetainedEarningsAccumulatedLosses 2025-03-31 10657848 core:LandBuildings core:OwnedOrFreeholdAssets 2025-04-01 2026-03-31 10657848 core:ComputerEquipment 2025-04-01 2026-03-31 10657848 core:LandBuildings core:OwnedOrFreeholdAssets 2025-03-31 10657848 core:ComputerEquipment 2025-03-31 10657848 2025-03-31 10657848 core:Non-currentFinancialInstruments 2026-03-31 10657848 core:Non-currentFinancialInstruments 2025-03-31 10657848 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 10657848 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 10657848 bus:FRS102 2025-04-01 2026-03-31 10657848 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 10657848 bus:FullAccounts 2025-04-01 2026-03-31 xbrli:pure xbrli:shares iso4217:GBP